Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
Cohort Studies of Memory in an International Consortium
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.
Lily Liu, a former communications professional in the non-profit sector, writes about her unique journey as an immigrant family caregiver in the United States and why she is a 'Dragon Daughter', even during the Year of the Ox.